Title:
AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia
Protocol Number:
PAALL0232
Phase:
Phase III
Physician:
Patrick Brown
Purpose:
The goal of this study is to increase this cure rate without increasing side effects of therapy (side effects are unintended results of treatment).
Eligibility:
-Age between 1 nad 30 years -Newly diagnosed B-precursor ALL -WBC Criteria a) Age 1.000-9.999 years: WBC e 50,000/µL b) Age 10.000-30.999 years: Any WBC c) Prior steroid therapy: Any WBC
Treatment:
The treatment on this study will consist of several phases. In the first phase, called induction, we try to remove all visible signs of leukemia and allow normal blood cells to be restored. In the middle phases, called consolidation, interim maintenance and delayed intensification, we try to deliver a knock-out punch to the remaining leukemia cells. In the final phase, called maintenance, we try to keep the leukemia from coming back (disease remission is when the leukemia seems to have disappeared). All phases of treatment are very important. The total length of treatment on this study will be approximately three years but does vary with gender.
Population:
Both
Last Update
06/18/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts